Success Metrics

Active Trials

7(78%)

Phase Distribution

Ph early_phase_1

11%

Ph phase_2

11%

Ph phase_1

44%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Early Phase 1First-in-human

1(11.1%)

Phase 1Safety & dosage

4(44.4%)

Phase 2Efficacy & side effects

1(11.1%)

Phase 3Large-scale testing

3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Terminated(1)

Detailed Status

Recruiting5

Active, not recruiting2

Not yet recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (11.1%)

Phase 14 (44.4%)

Phase 21 (11.1%)

Phase 33 (33.3%)

Trials by Status

not_yet_recruiting111%

active_not_recruiting222%

recruiting556%

withdrawn111%

Recent Activity

7 active trials

Showing 5 of 9

active_not_recruitingphase_1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

NCT06899061

active_not_recruitingphase_3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491

recruitingphase_1

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168

recruitingphase_3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803

not_yet_recruitingphase_3

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT06899061Phase 1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Active Not Recruiting

NCT06120491Phase 3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Active Not Recruiting

NCT05797168Phase 1

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Recruiting

NCT06952803Phase 3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Recruiting

NCT07711002Phase 3

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Not Yet Recruiting

NCT07446855Phase 1

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Recruiting

NCT06769126Phase 2

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Recruiting

NCT04005690Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting

NCT07060365Phase 1

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9